<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Mol Neuropsychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol Neuropsychiatry</journal-id>
<journal-id journal-id-type="publisher-id">MNP</journal-id>
<journal-title-group>
<journal-title>Molecular Neuropsychiatry</journal-title>
</journal-title-group>
<issn pub-type="ppub">2296-9209</issn>
<issn pub-type="epub">2296-9179</issn>
<publisher>
<publisher-name>S. Karger AG</publisher-name>
<publisher-loc>Allschwilerstrasse 10, P.O. Box · Postfach · Case postale, CH–4009, Basel, Switzerland · Schweiz · Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.ch</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27606321</article-id>
<article-id pub-id-type="pmc">4996009</article-id>
<article-id pub-id-type="doi">10.1159/000445802</article-id>
<article-id pub-id-type="publisher-id">mnp-0002-0061</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Genetics of Common Antipsychotic-Induced Adverse Effects</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>MacNeil</surname>
<given-names>Raymond R.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Müller</surname>
<given-names>Daniel J.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>c</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>d</sup>
</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
</contrib-group>
<aff id="aff1"><sup>a</sup>Mood Research Laboratory, Department of Psychology, Queen's University, Kingston, Ont., Canada</aff>
<aff id="aff2"><sup>b</sup>Departments of Psychiatry, University of Toronto, Toronto, Ont., Canada</aff>
<aff id="aff3"><sup>c</sup>Departments of Pharmacology and Toxicology, University of Toronto, Toronto, Ont., Canada</aff>
<aff id="aff4"><sup>d</sup>Pharmacogenetics Research Clinic, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ont., Canada</aff>
<author-notes>
<corresp id="cor1">*Daniel J. Müller, MD, PhD, Centre for Addiction and Mental Health, 250 College Street, R132, Toronto, ON M5T 1R8 (Canada), E-Mail <email>daniel.mueller@camh.ca</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>7</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>20</day>
<month>5</month>
<year>2016</year>
</pub-date>
<volume>2</volume>
<issue>2</issue>
<fpage>61</fpage>
<lpage>78</lpage>
<history>
<date date-type="received">
<day>23</day>
<month>11</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>24</day>
<month>3</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2016 by S. Karger AG, Basel</copyright-statement>
<copyright-year>2016</copyright-year>
</permissions>
<abstract>
<p>The effectiveness of antipsychotic drugs is limited due to accompanying adverse effects which can pose considerable health risks and lead to patient noncompliance. Pharmacogenetics (PGx) offers a means to identify genetic biomarkers that can predict individual susceptibility to antipsychotic-induced adverse effects (AAEs), thereby improving clinical outcomes. We reviewed the literature on the PGx of common AAEs from 2010 to 2015, placing emphasis on findings that have been independently replicated and which have additionally been listed to be of interest by PGx expert panels. Gene-drug associations meeting these criteria primarily pertain to metabolic dysregulation, extrapyramidal symptoms (EPS), and tardive dyskinesia (TD). Regarding metabolic dysregulation, results have reaffirmed <italic>HTR2C</italic> as a strong candidate with potential clinical utility, while <italic>MC4R</italic> and <italic>OGFR1</italic> gene loci have emerged as new and promising biomarkers for the prediction of weight gain. As for EPS and TD, additional evidence has accumulated in support of an association with <italic>CYP2D6</italic> metabolizer status. Furthermore, <italic>HSPG2</italic> and <italic>DPP6</italic> have been identified as candidate genes with the potential to predict differential susceptibility to TD. Overall, considerable progress has been made within the field of psychiatric PGx, with inroads toward the development of clinical tools that can mitigate AAEs. Going forward, studies placing a greater emphasis on multilocus effects will need to be conducted.</p>
</abstract>
<kwd-group>
<title>Key Words</title>
<kwd>Antipsychotic</kwd>
<kwd>Adverse effect</kwd>
<kwd>Extrapyramidal symptoms</kwd>
<kwd>Genetic association study</kwd>
<kwd>Metabolic syndrome</kwd>
<kwd>Pharmacogenetics</kwd>
<kwd>Polymorphism</kwd>
<kwd>Tardive dyskinesia</kwd>
<kwd>Weight gain</kwd>
</kwd-group>
<counts>
<table-count count="4"></table-count>
<ref-count count="157"></ref-count>
<page-count count="18"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>